Virus-free iPS-derived cardiomyocytes: a new piece in the puzzle of patient-tailored therapies.

The potential of human embryonic stem (hES) cells for therapeutic purposes became immediately clear after their derivation by Thomson’s group in 1998. It was also clear, though, that their origin represented their main limitation. The ethical and legislative issues challenging hES cell-based research have produced a ‘selective pressure’ in response to which… (More)